title: Immunomodulatory and physical effects of phospholipid composition in vaccine adjuvant emulsions.
abstract: Egg phosphatidylcholine is commonly used as an emulsifier in formulations administered parenterally. However, synthetic phosphatidylcholine (PC) emulsifiers are now widely available and may be desirable substitutes for egg-derived phospholipids due to stability, purity, and material source considerations. In earlier work, we demonstrated that a squalene-1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) emulsion provided equivalent physical stability compared to a squalene-egg PC emulsion. In the present manuscript, we evaluate the physical stability of vaccine adjuvant emulsions containing a range of other synthetic phosphatidylcholine emulsifiers. Besides the POPC emulsion, the 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) emulsion showed good particle size and visual stability compared to emulsions made with other synthetic phospholipids. Moreover, comparable immune responses were elicited by squalene emulsions employing various synthetic PC or egg PC emulsifiers in combination with an inactivated influenza vaccine or a recombinant malaria antigen, and these responses were generally enhanced compared to antigen without adjuvant. Therefore, we show that (1) some synthetic PCs (DMPC, POPC, and to a lesser extent 1,2-dioleoyl-sn-glycero-3-phosphocholine) are effective stabilizers of squalene emulsion over a range of storage temperatures while others are not (1,2-distearoyl-sn-glycero-3-phosphocholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine, and 1,2-dilauroyl-sn-glycero-3-phosphocholine) and (2) the immunogenicity of stable squalene emulsions is similar regardless of PC source.
authors.affiliation: Infectious Disease Research Institute, 1124 Columbia St, Ste 400, Seattle, Washington 98104, USA. cfox@idri.org
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Fox
authors.forename: Susan L
authors.initials: SL
authors.lastname: Baldwin
authors.forename: Malcolm S
authors.initials: MS
authors.lastname: Duthie
authors.forename: Steven G
authors.initials: SG
authors.lastname: Reed
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Vedvick
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000737:chemistry; D000818:Animals; D000906:Antibodies / Q000097:blood; D002626:Chemistry, Pharmaceutical; D004134:Dimyristoylphosphatidylcholine / Q000737:chemistry / Q000276:immunology; D004355:Drug Stability; D045703:Emulsifying Agents / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D004655:Emulsions; D005260:Female; D006801:Humans; D007114:Immunization; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D007273:Injections, Intramuscular; D017780:Malaria Vaccines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D010316:Particle Size; D010713:Phosphatidylcholines / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D013185:Squalene / Q000737:chemistry / Q000276:immunology; D013678:Technology, Pharmaceutical / Q000379:methods; D013997:Time Factors
chemical_list: D000276:Adjuvants, Immunologic; D000906:Antibodies; D045703:Emulsifying Agents; D004655:Emulsions; D007252:Influenza Vaccines; D017780:Malaria Vaccines; D010713:Phosphatidylcholines; D013185:Squalene; C028694:1-palmitoyl-2-oleoylphosphatidylcholine; D004134:Dimyristoylphosphatidylcholine